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Abstract
Patient-derived xenograft (PDX) tumors are powerful tools to study cancer biology. How-
ever, the ability of PDX tumors to model the biological and histological diversity of pancreatic
ductal adenocarcinoma (PDAC) is not well known. In this study, we subcutaneously im-
planted 133 primary and metastatic PDAC tumors into immunodeficient mice. Fifty-seven
tumors were successfully engrafted and even after extensive passaging, the histology of
poorly-, moderately-, and well-differentiated tumors was maintained in the PDX models.
Moreover, the fibroblast and collagen contents in the stroma of patient tumors were recapit-
ulated in the corresponding PDX models. Analysis of the clinicopathological features of
patients revealed xenograft tumor engraftment was associated with lymphovascular inva-
sion (P = 0.001) and worse recurrence-free (median, 7 vs. 16 months, log-rank P = 0.047)
and overall survival (median, 13 vs. 21 months, log-rank P = 0.038). Among successful
engraftments, median time of growth required for reimplantation into new mice was 151
days. Reflective of the inherent biological diversity between PDX tumors with rapid (<151
days) and slow growth, differences in their growth were maintained during extensive pas-
saging. Rapid growth was additionally associated with lymph node metastasis (P = 0.022).
The association of lymphovascular invasion and lymph node metastasis with PDX formation
and rapid growth may reflect an underlying biological mechanism that allows these tumors
to adapt and grow in a new environment. While the ability of PDX tumors to mimic the cellu-
lar and non-cellular features of the parental tumor stroma provides a valuable model to
study the interaction of PDAC cells with the tumor microenvironment, the association of
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successful engraftment with adverse clinicopathological features suggests PDX models
over represent more aggressive forms of this disease.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic cancer, with more
than 53,000 cases diagnosed per year in the United States. Only 8% of these patients survive
beyond five years, making PDAC the fourth leading cause of cancer-related deaths [1]. The
ineffectiveness of treatments and the scant improvement of survival outcomes may be ascribed
to the fact that PDAC has historically been modeled as a single disease entity. By contrast,
recent advances in genomics have revealed the heterogeneity of this disease [2–4]. Although
activating mutations in KRAS occur in ~90% of PDAC, there are few additional genes (such as
TP53 and SMAD4) commonly mutated or inactivated in pancreatic cancer [5]. Contributing
to the challenges associated with treating PDAC is a highly desmoplastic stroma that promotes
the aggressive local growth of the tumor and the intrinsic chemo-resistance of the cancer cells
[6–9]. Thus, modeling the tumor microenvironment and its crosstalk with the cancer cells is
particularly important in developing new therapies for PDAC.
Several in vitro and in vivo preclinical models are available to study the biology of cancer,
including cell lines and xenograft tumors derived from them, genetically-engineered mouse
models, organoids, and patient-derived xenograft (PDX) tumor models [10,11]. Among these,
PDX tumors have the advantage of mimicking the genetic complexity of human PDAC in a
platform that has the potential to recapitulate many of the features of the tumor microenviron-
ment. Moreover, a model that faithfully reflects the original tumor biology may predict clinical
outcomes and allow for the development of personalized targeted therapies [12–15]. However,
the growth of PDX tumors from pancreatic cancer is variable and the determinants of their
growth are unknown [16–19].
Understanding the dynamic behind xenograft tumor formation, the features that affect the
success of tumor engraftment, and the prognostic implications could be an important key for
new perspectives in the knowledge of pancreatic cancer. The aims of our study were to identify
clinical and pathological factors associated with successful tumor engraftment and xenograft
growth rate, and to evaluate whether tumor engraftment and xenograft rate of growth were
prognostic of patient outcomes. We also analyzed PDX tumors to assess the ability of these
models to reproduce the histological features of the original pancreatic tumors.
Materials and methods
Patient population and tumor samples
All study participants provided IRB-approved informed consent for their medical records and
tissue samples to be used in this study. Patient clinical data was entered into a de-identified
clinical database allowing for the anonymous analysis of demographic, clinical and pathologi-
cal variables. We collected fresh tumor samples from 133 patients with histologically-con-
firmed stages I-IV PDAC who underwent surgery for curative intent, diagnostic laparoscopy,
or palliation of symptoms at the Massachusetts General Hospital between April, 2009 and July,
2012.
Xenograft tumors
Patient tumor samples were mechanically minced into small fragments (1–2 mm3) and either
implanted into mice or cryopreserved in freezing media (10% DMSO, 20% FBS, 70% DMEM/
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Ham’s F-12 50/50 supplemented with 1% PS) for future implantation. Cryopreserved tumors
were rapidly thawed in a 37˚C water bath and washed twice with PBS prior to implantation.
For tumor implantation, 6–8 week-old nu/j mice (Jackson Laboratory) were anesthetized with
Isoflurane and a small incision made on the dorsal flank. Approximately 70–100 mg of tumor
tissue coated in 50–100 of μl of Matrigel (Corning, 354248) was subcutaneously implanted
into the flank of each mouse and the incision was closed with a single suture (4–0 Coated
Vicryl, Ethicon). Mice were administered buprenorphine as needed as an analgesic. Patient
tumors were implanted in a median number of 4 mice (range 1–5). In 10.5% of cases the
tumor tissue was enough for only one mouse. Mice were monitored weekly for tumor growth.
Mice that lacked a palpable tumor after 6 months were removed from the study and the patient
tumors were categorized as no engraftment. Successful tumor engraftment was defined as
tumors that grew large enough (1 cm) to be reimplanted into new mice. Mice with tumors < 1
cm after 180 days were retained in the study until tumors reached sufficient size for reimplan-
tation. Tumors implanted in mice that were removed from the study due to health reasons
before the tumor reached an appropriate size for reimplantation were categorized as no
engraftment. For tumors that successfully formed xenografts, we recorded the time of growth
between initial implantation and reimplantation into new mice. The presence of pancreatic
adenocarcinoma in xenograft tumors was confirmed by histological analysis of hematoxylin
and eosin (H&E) stained sections by pathologists with a special interest in pancreatic cancer
(M.M.K. and M.W.R). Maximum tumor size in this study did not exceed 1.5 cm. Mice were
euthanized by CO2 asphyxiation in accordance to the guidelines set forth in the American Vet-
erinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals.
Immunohistochemistry
Representative sections of primary human tumors were stained with a 1:50 dilution of a goat
polyclonal antibody specific to SMAD4 (sc-1909, Santa Cruz Biotechnology, Dallas, TX, USA)
using the Bond RX IHC staining platform (Leica Biosystems, Buffalo Grove, IL, USA) with
BOND Epitope Retrieval Solution 2 (Leica Biosystems, AR9640). The staining of SMAD4 was
scored by a pathologist and SMAD4 expression was considered preserved (positive) when
detected in the nucleus and/or cytoplasm of PDAC cells. Staining of stromal cells in each
tumor section was used as an internal positive control. For analysis of cancer-associated fibro-
blasts, deparaffinized sections of patient and PDX tumors were stained with a 1:200 dilution of
a rabbit polyclonal antibody specific to alpha smooth muscle actin (ab5694, Abcam, Cam-
bridge, MA, USA) as described previously [20]. The collagen content of tumors was visualized
by picrosirius red staining (Picro Sirius Red Stain Kit, Abcam, Cambridge, MA, USA).
Genetic analysis of patient tumors
DNA extracted from formalin-fixed paraffin-embedded tumor samples from 20 patients was
analyzed for somatic mutations using SNaPshot multiplex assays (Applied Biosystems) [21].
Common to these assays were the tests for variants in loci found in APC, BRAF,CTNNB1,
EGFR,KIT, KRAS, NOTCH1,NRAS, PI3KA, PTEN, and TP53. On average, approximately 5%
mutant allele is sufficient for detection in these assays. Only mutations in KRAS and TP53
were detected in our series.
Outcome measures
The primary outcome measures of this study were successful tumor engraftment and xenograft
rate of growth. We also evaluated whether tumor engraftment and xenograft growth rate were
associated with patient recurrence-free survival (RFS) and overall survival (OS). RFS was
Pancreatic cancer xenograft tumor models and patient outcomes
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defined as time between surgery and evidence of disease recurrence or death from any cause;
analyses of RFS were restricted to patients with resectable primary tumors and no evidence of
metastatic disease (n = 112). OS was defined as time between surgery and death from any
cause; analyses of OS were performed in the entire study population. Follow-up continued
through February, 2017.
Statistical analysis
We evaluated the associations of clinical and pathological features with tumor engraftment
and xenograft rate of growth using univariate analyses. Analyses of categorical data were per-
formed using chi-square or Fisher exact tests, where appropriate; continuous data were ana-
lyzed with Mann-Whitney U test. Associations of tumor engraftment and xenograft growth
rate with patient survival were analyzed using log-rank tests and multivariable-adjusted Cox
proportional hazards regression adjusting for potential confounders. Kaplan-Meier survival
curves, median survival time, and two- and five-year survival rates were also presented. Cox
regression models adjusted for patient age and sex, receipt of neoadjuvant and adjuvant ther-
apy, American Joint Committee on Cancer (7th edition) clinical stage, tumor differentiation
grade, presence of lymphovascular invasion, surgical margins, and tumor location. Statistical
significance was set at P<0.05 and all hypothesis tests were two-sided. Statistical analyses were
conducted using SAS software (version 9.4; SAS Institute, Cary, NC).
Results
Primary or metastatic tumor samples were collected from 133 patients with histologically-con-
firmed diagnosis of PDAC. The baseline characteristics of patients in our study are presented
in Tables 1 and 2. The median age of the patients in our study was 68 (range 35–93). Fifty-
seven (43%) tumors implanted into immunodeficient mice were successfully engrafted, while
76 (57%) failed to do so. A number of studies have reported different methods of cryopreserv-
ing tumors for future growth as xenograft tumors [22,23]. In our study, there was no signifi-
cant difference in the engraftment rate between freshly implanted (n = 24) and cryopreserved
(n = 109) tumors (50% vs 41%, P = 0.498).
Histological analysis of the xenograft tumors revealed that the grade of differentiation of
the human tumors was retained in each of the corresponding xenografts. Moreover, the histol-
ogy of poorly-, moderately-, and well-differentiated tumors was retained through at least 10
generations in mice (Fig 1A). Characteristic of the stroma of PDAC tumors is the presence of
cancer associated fibroblasts and abundance of collagen. The corresponding xenograft tumors
contain α-smooth muscle actin-expressing fibroblasts similarly to patient tumors (Fig 1B).
Furthermore, picrosirius red staining revealed that collagen content of xenograft tumors was
largely composed of either organized or disorganized fibers and these collagen subtypes were
similarly found within the malignant epithelium of the corresponding patient tumor (Fig 1B).
Collectively, these results demonstrate that patient-derived xenograft models of PDAC retain
the histological and microenvironmental characteristics of the original tumor.
Clinical and genetic characteristics, pathological features, and tumor
engraftment status
To gain insight into the factors that determine tumor engraftment, we evaluated the demo-
graphic, clinical, and pathological characteristics of patients based on tumor engraftment sta-
tus (Tables 1 and 2). We found no significant associations between demographic or clinical
features and tumor engraftment. Neoadjuvant chemotherapy has become increasingly com-
mon in patients with PDAC and is associated with increased fibrosis and a reduction in viable
Pancreatic cancer xenograft tumor models and patient outcomes
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Table 1. Baseline demographic and clinical characteristics of 133 patients with resected pancreatic ductal adenocarcinoma by tumor engraftment
status.
Overall Tumor engraftment
Yes No P value
No. Patients 133 57 (43%) 76 (57%)
Men, n (%) 70 (53%) 34 (60%) 36 (47%) 0.160
Age, median (IQR) 68 (18) 66 (16) 70 (18.5) 0.730
Serum CA19-9, median (IQR) 128 (376.6) 118 (347.0) 128.5 (436.5) 0.916
Body mass index, median (IQR) 25.9 (6.0) 26.8 (6.3) 25.2 (6.0) 0.390
Diabetes, n (%)
No 101 (76%) 41 (72%) 60 (79%) 0.345
Yes 32 (24%) 16 (28%) 16 (21%)
New-onset or worsening diabetes, n (%)*
No 11 (34%) 6 (37%) 5 (31%) 0.809
Yes 20 (63%) 10 (63%) 10 (63%)
Unknown 1 (3%) - 1 (6%)
Neoadjuvant therapy, n (%)
No 91 (68%) 42 (74%) 49 (64%) 0.258
Yes 42 (32%) 15 (26%) 27 (36%)
Resection, n (%)
No 17 (13%) 9 (16%) 8 (11%) 0.368
Yes 116 (87%) 48 (84%) 68 (89%)
Metastatic disease, n (%)
No 112 (84%) 45 (79%) 67 (88%) 0.149
Yes 21 (16%) 12 (21%) 9 (12%)
Type of resection, n (%)
Whipple 91 (68%) 34 (59%) 57 (75%) 0.131
Middle 4 (3%) 1 (2%) 3 (4%)
Distal 20 (15%) 13 (23%) 7 (9%)
Total 1 (1%) - 1 (1%)
No resection 17 (13%) 9 (16%) 8 (11%)
Adjuvant therapy, n (%)**
No 30 (27%) 10 (22%) 20 (30%) 0.421
Yes 79 (70%) 33 (73%) 46 (69%)
Unknown 3 (3%) 2 (5%) 1 (1%)
Recurrence, n (%)**
No 28 (25%) 9 (20%) 19 (28%) 0.317
Yes 84 (75%) 36 (80%) 48 (72%)
Site of recurrence, n (%)***
Locoregional 21 (25%) 9 (25%) 12 (25%) 0.488
Distant 54 (64%) 24 (67%) 30 (63%)
Both locoregional and distant 8 (10%) 2 (5%) 6 (12%)
Unknown 1 (1%) 1 (3%) -
Abbreviations: IQR, interquartile range.
*Among patients with diabetes mellitus (n = 32).
** Among patients undergoing resection with curative intent and absence of metastatic disease (n = 112).
*** Among patients with evidence of recurrence following resection with curative intent (n = 84).
https://doi.org/10.1371/journal.pone.0182855.t001
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Table 2. Pathological characteristics of 133 patients with resected pancreatic ductal adenocarcinoma by tumor engraftment status.
Overall Tumor engraftment
Yes No P value
No. Patients 133 57 (43%) 76 (57%)
Tumor differentiation grade, n (%)
Well differentiated 7 (5%) 3 (5%) 4 (5%) 0.846
Moderately differentiated 65 (49%) 26 (46%) 39 (52%)
Poorly differentiated 53 (40%) 24 (42%) 29 (38%)
Unknown 8 (6%) 4 (7%) 4 (5%)
AJCC 7th ed. stage, n (%)
IA 1 (1%) 1 (2%) - 0.333
IB 6 (4%) 2 (3%) 4 (5%)
IIA 17 (13%) 5 (9%) 12 (16%)
IIB 88 (66%) 37 (65%) 51 (67%)
III - - -
IV 21 (16%) 12 (21%) 9 (12%)
AJCC 7th ed. pT, n (%)*
pT1 2 (2%) 1 (2%) 1 (2%) 0.928
pT2 11 (10%) 4 (9%) 7 (10%)
pT3 99 (88%) 40 (89%) 59 (88%)
pT4 - - -
AJCC 7th ed. pN, n (%)*
pN0 24 (21%) 8 (18%) 16 (24%) 0.440
pN1 88 (79%) 37 (82%) 51 (76%)
Tumor location, n (%)
Body/Tail 30 (23%) 18 (32%) 12 (16%) 0.031
Head/Uncinante 103 (77%) 39 (68%) 64 (84%)
Size cm, median (IQR)* 3.0 (1.5) 3.5 (1.7) 2.8 (1.6) 0.051
Lymphovascular invasion, n (%)
Absent 40 (30%) 8 (14%) 32 (42%) 0.001
Present 81 (61%) 43 (75%) 38 (50%)
Unknown 12 (9%) 6 (11%) 6 (8%)
Perineural invasion, n (%)
Absent 6 (4%) 2 (3%) 4 (5%) 0.681
Present 110 (83%) 46 (81%) 64 (84%)
Unknown 17 (13%) 9 (16%) 8 (11%)
Surgical margins, n (%)*
R0 98 (87%) 41 (91%) 57 (85%) 0.532
R1 13 (12%) 4 (9%) 9 (13%)
R2 1 (1%) - 1 (2%)
SMAD4, n (%)**
Retained 40 (62%) 20 (69%) 20 (57%) 0.331
Lost 24 (38%) 9 (31%) 15 (43%)
Abbreviations: IQR, interquartile range.
*Among patients undergoing resection with curative intent and absence of metastatic disease (n = 112).
**Among tumors with available SMAD4 immunohistochemistry (n = 64).
https://doi.org/10.1371/journal.pone.0182855.t002
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cancer cells, which could influence the ability of a tumor to successfully establish a xenograft
[24]. Notably, 42 (32%) patients in our series received neoadjuvant chemotherapy and this did
not adversely affect tumor engraftment (Table 1).
Analysis of pathological features of patient tumors demonstrated that lymphovascular inva-
sion and location of the primary tumor within the pancreas were significantly associated with
tumor engraftment. Tumors with successful engraftment had higher frequency of lymphovas-
cular invasion (43/57, 75%) compared to tumors that did not form xenografts (38/76, 50%;
P = 0.001). Among patients whose tumors successfully engrafted, primary tumors were located
Fig 1. PDX models of PDAC retain the histological and stromal features of the parental tumor. (A) H&E staining of well-
differentiated (grade 1), moderately-differentiated (grade 2) and poorly-differentiated (grade 3) tumors. The primary patient tumor and
corresponding passages of the PDX models are shown. Scale bars = 100 μm. (B) Immunohistochemistry for α-smooth muscle actin
(SMA; top panels) and picrosirius red staining for collagen (bottom panels) was performed on representative PDX models and
corresponding patient tumors. Scale bars = 100 μm.
https://doi.org/10.1371/journal.pone.0182855.g001
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in the body and tail of the pancreas in 32% (18/57) of cases; in contrast, only 16% (12/76) of
primary tumors that did not engraft were located in the pancreatic body and tail (P = 0.031).
Features such as tumor grade, nodal metastases, or type of implanted tumor tissue (i.e., pri-
mary vs. metastatic) were not significantly associated with engraftment status.
To evaluate whether common molecular alterations found in PDAC are associated with
tumor engraftment, we performed genetic analysis of KRAS and TP53, and immunohis-
tochemistry for SMAD4. Genetic analysis of engrafted and non-engrafted tumors revealed 18/
20 (90%) tumors contained activating mutations in codon 12 or 61 of KRAS, while hot spot
mutations in TP53were identified in three (15%) tumors (Fig 2A). However, there was no
association between these mutations and the success of tumor engraftment. SMAD4 is fre-
quently inactivated in PDAC through both genetic and epigenetic mechanisms [25]. There-
fore, we employed immunohistochemistry to evaluate the expression of SMAD4 in 64 patient
tumors, 45% of which were successfully engrafted (Fig 2B). The expression of SMAD4 was lost
in 38% of tumors, and there was no significant difference in the loss of SMAD4 expression
between engrafted and non-engrafted tumors (31% vs 43%, P = 0.331, Fig 2C). Taken together,
these results suggest that alterations in these core PDAC pathways are not predictive of tumor
engraftment.
Clinical characteristics, pathological features, and xenograft growth rate
Among successful engraftments, the median time of growth required for reimplantation into
new mice was 151 days (range 39–346 days; Fig 3A). Xenograft tumors that were reimplanted
in less than 151 days were defined as having a rapid growth rate. Analysis of representative
rapid and slow ( 151 days) xenograft tumor lines revealed that the relative differences in the
growth rate of these tumors was maintained for at least 10 generations (Fig 3B). Since these dif-
ferences in the time to tumor engraftment may be related to the inherent characteristics of the
Fig 2. Molecular characteristics of patient tumors do not predict tumor engraftment. (A) Genetic analysis of KRAS and
TP53 in patient tumors. Amino acid changes resulting from mutations are listed. Samples for which mutations were not detected
are indicated by a dash. (B) Representative positive and negative immunohistochemical staining of SMAD4 in primary patient
tumors. Staining of stromal cells on each slide served as a positive control. Scale bars = 100 μm. (C) Summary of SMAD4
expression in patient tumors that were successfully or unsuccessfully engrafted in mice.
https://doi.org/10.1371/journal.pone.0182855.g002
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tumor biology, we performed a comparison of the clinical (Table 3) and pathological (Table 4)
features between tumors with rapid and slow growth. Rapid growth was significantly associ-
ated with patients of male gender (P = 0.020), primary tumors located in the head of the pan-
creas (P = 0.029), and lymph node metastases (P = 0.022). Collectively, our results suggest that
both tumor engraftment and xenograft growth rate are associated with adverse pathological
features (e.g. lymphovascular for tumor engraftment and lymph node metastases for xenograft
growth rate).
Tumor engraftment, rate of growth, and survival outcomes
To determine the prognostic value of tumor engraftment, we analyzed the relationship
between patient survival outcomes and PDX formation and growth rate. Overall, 30 (22.6%)
Fig 3. The time to tumor engraftment correlates with the rate of PDX tumor growth. (A) Time to tumor
engraftment was grouped in 30-day intervals and the frequency of their occurrence is shown on the left y-axis.
The cumulative percentage of tumors engrafted over time is shown on the right y-axis. (B) The growth of PDX
tumors that exhibited rapid and slow engraftment. The median and standard deviation of tumors for passages
2–10 are shown. Passage 1 tumors represent the founding PDX tumor from which subsequent PDX
passages were derived.
https://doi.org/10.1371/journal.pone.0182855.g003
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patients of our cohort were alive at the end of follow-up period, and among them the median
follow up time was 45 months. In patients who underwent resection with curative intent with-
out evidence of metastatic disease, the median, 2-year, and 5-year RFS was 10 months (95% CI
Table 3. Baseline demographic and clinical characteristics of 57 patients with patient-derived PDAC xenografts based on xenograft growth rate.
Overall Xenograft Growth
Rapid Slow P value
No. patients 57 28 (49%) 29 (51%)
Men, n (%) 34 (60%) 21 (75%) 13 (45%) 0.020
Age, median (IQR) 66 (16.0) 66 (11.5) 71 (24) 0.193
Serum CA19-9, median (IQR) 118 (347.0) 145 (376.5) 94 (195.0) 0.429
Body mass index, median (IQR) 26.8 (6.3) 27.3 (7.9) 26.3 (5.3) 0.334
Diabetes, n (%)
No 41 (72%) 20 (71%) 21 (72%) 0.934
Yes 16 (28%) 8 (29%) 8 (28%)
New-onset or worsening diabetes, n (%)*
No 6 (37%) 2 (25%) 4 (50%) 0.608
Yes 10 (63%) 6 (75%) 4 (50%)
Neoadjuvant therapy, n (%)
No 42 (74%) 20 (71%) 22 (76%) 0.704
Yes 15 (26%) 8 (29%) 7 (24%)
Resection, n (%)
No 9 (16%) 4 (14%) 5 (17%) 1.00
Yes 48 (84%) 24 (86%) 24 (83%)
Metastatic disease, n (%)
No 45 (79%) 23 (82%) 22 (76%) 0.561
Yes 12 (21%) 5 (18%) 7 (24%)
Type of resection, n (%)
Whipple 34 (59%) 20 (72%) 14 (48%) 0.253
Middle 1 (2%) - 1 (4%)
Distal 13 (23%) 4 (14%) 9 (31%)
Total - - -
No resection 9 (16%) 4 (14%) 5 (17%)
Adjuvant therapy, n (%)**
No 10 (22%) 3 (13%) 7 (32%) 0.281
Yes 33 (73%) 18 (78%) 15 (68%)
Unknown 2 (5%) 2 (9%) -
Recurrence, n (%)**
No 9 (20%) 3 (13%) 6 (27%) 0.284
Yes 36 (80%) 20 (87%) 16 (73%)
Site of recurrence, n (%)***
Locoregional 9 (25%) 5 (25%) 4 (25%) 0.412
Distant 24 (67%) 13 (65%) 11 (69%)
Both locoregional and distant 2 (5%) 2 (10%) -
Unknown 1 (3%) - 1 (6%)
Abbreviations: IQR, interquartile range.
*Among patients with diabetes mellitus (n = 16).
** Among patients undergoing resection with curative intent and absence of metastatic disease (n = 45).
*** Among patients with evidence of recurrence following resection with curative intent (n = 36).
https://doi.org/10.1371/journal.pone.0182855.t003
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7–15), 25.3%, and 12.7%, respectively. In the entire study population, the median, 2-year, and
5-year OS was 16 months (95% CI 13–19), 38.0%, and 14.7%, respectively.
Table 4. Baseline pathological characteristics of 57 patients with patient-derived PDAC xenografts based on xenograft growth rate.
Overall Xenograft Growth
Rapid Slow P value
No. patients 57 28 (49%) 29 (51%)
Tumor differentiation grade, n (%)
Well differentiated 3 (5%) 1 (4%) 2 (7%) 0.728
Moderately differentiated 26 (46%) 14 (50%) 12 (41%)
Poorly differentiated 24 (42%) 11 (39%) 13 (45%)
Unknown 4 (7%) 2 (7%) 2 (7%)
AJCC 7th ed. stage, n (%)
IA 1 (2%) - 1 (3.5%) 0.106
IB 2 (3%) 1 (3%) 1 (3.5%)
IIA 5 (9%) - 5 (17%)
IIB 37 (65%) 22 (79%) 15 (52%)
III - - -
IV 12 (21%) 5 (18%) 7 (24%)
AJCC 7th ed. pT, n (%)*
pT1 1 (2%) - 1 (4%) 0.304
pT2 4 (9%) 1 (4%) 3 (14%)
pT3 40 (89%) 22 (96%) 18 (82%)
pT4 - - -
AJCC 7th ed. pN, n (%)*
pN0 8 (18%) 1 (4%) 7 (32%) 0.022
pN1 37 (82%) 22 (96%) 15 (68%)
Tumor location, n (%)
Body/Tail 18 (32%) 5 (18%) 13 (45%) 0.029
Head/Uncinante 39 (68%) 23 (82%) 16 (55%)
Size cm, median (IQR)* 3.5 (1.7) 3.3 (1.7) 3.7 (1.5) 0.910
Lymphovascular invasion, n (%)
Absent 8 (14%) 2 (7%) 6 (21%) 0.140
Present 43 (75%) 24 (86%) 19 (65%)
Unknown 6 (11%) 2 (7%) 4 (14%)
Perineural invasion, n (%)
Absent 2 (3%) - 2 (7%) 0.489
Present 46 (81%) 24 (86%) 22 (76%)
Unknown 9 (16%) 4 (14%) 5 (17%)
Surgical margins, n (%)*
R0 41 (91%) 22 (96%) 19 (86%) 0.346
R1 4 (9%) 1 (4%) 3 (14%)
R2 - - -
SMAD4, n (%)**
Retained 20 (69%) 12 (67%) 8 (73%) 1.000
Lost 9 (31%) 6 (33%) 3 (27%)
Abbreviations: IQR, interquartile range.
*Among patients undergoing resection with curative intent and absence of metastatic disease (n = 45).
**Among tumors with available SMAD4 immunohistochemistry (n = 29).
https://doi.org/10.1371/journal.pone.0182855.t004
Pancreatic cancer xenograft tumor models and patient outcomes
PLOS ONE | https://doi.org/10.1371/journal.pone.0182855 August 30, 2017 11 / 17
Patients with tumors that successfully engrafted had significantly shorter RFS (median, 7
vs. 16 months, log-rank P = 0.047; Fig 4A) and OS (median, 13 vs. 21 months, log-rank
P = 0.038; Fig 4B) compared to patients with tumors that failed to engraft. Moreover, the mul-
tivariable-adjusted survival analyses revealed tumor engraftment as an independent predictor
of worse RFS (HR 2.05, 95% CI 1.20–3.50, P = 0.009) (Table 5). Survival analyses based on
xenograft growth rate did not show significant associations with patient survival outcomes,
although analyses were limited by sample size (Table 5, Fig 4C and 4D). Patients with rapid-
growing xenografts had shorter RFS (median, 6 vs. 10 months, log-rank P = 0.189) and OS
(median, 8 vs. 14, log-rank P = 0.328) than those with slow-growing xenografts, although these
differences were not statistically significant.
Discussion
The genetic heterogeneity of PDAC and the intense desmoplastic reaction of the tumor stroma
have made improvements in survival outcomes difficult to achieve. Preclinical models that
Fig 4. PDAC tumor engraftment in mice is associated with poor patient outcomes. (A) Kaplan-Meier curves of recurrence-
free survival and tumor engraftment for patients with resectable primary tumors and no evidence of metastatic disease. (B) Kaplan-
Meier curves of overall survival and tumor engraftment for the entire study population. (C) Kaplan-Meier curves of recurrence-free
survival and rate of tumor engraftment for patients with resectable primary tumors and no evidence of metastatic disease. (D)
Kaplan-Meier curves of overall survival and rate of tumor engraftment for the entire study population.
https://doi.org/10.1371/journal.pone.0182855.g004
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closely recapitulate the complexity of human pancreatic cancer are indispensable to study the
biology of this disease and assess novel therapeutic agents. In this setting, PDX tumor models
of PDAC allow for the faithful propagation of the human neoplastic cells. We showed that the
histological architecture of the original tumors is maintained in the PDX models for different
grades of differentiation, even after extensive passages. Moreover, although the non-malignant
stroma of the human tumor is replaced with cells from the host mouse, these components
seem to mimic several features of the original tumor stroma, including cancer-associated
fibroblasts (CAFs) and tumor vasculature [26–28]. In PDAC, the CAFs are largely responsible
for the production of the extracellular matrix found in the tumor stroma, and the production
of collagen by CAFs is mediated by their close association with PDAC cells [29,30]. Despite the
replacement of human CAFs by murine fibroblasts, we demonstrated that the collagen struc-
tures found in PDX models of PDAC closely resemble those found in the original tumor.
Therefore, PDX tumors provide a system to investigate the cellular and non-cellular compo-
nents of the stroma and their interactions with PDAC cells.
The pathological factors associated with PDX formation have been described for a variety
of cancers [31,32]. However, their identification in PDAC has largely remained elusive, with a
single study correlating tumor size (> 3.5 cm) with successful xenograft generation [16,18,19].
In our series, we identified lymphovascular invasion and lymph node metastasis as potential
determinants for PDX formation and rapid growth, respectively. An important role for lym-
phovascular invasion is highlighted by the fact that only 14% of tumors without lymphovascu-
lar invasion successfully engrafted. These results suggest that engraftment may reflect an
underlying biological mechanism that allows these tumors to adapt and grow in a new envi-
ronment. Interestingly, previous studies employing NOD/SCID mice have failed to make simi-
lar correlations with these pathological features and PDAC engraftment and growth [16–18].
While the more immunocompromised background of these mice likely allows for more effi-
cient tumor engraftment, it is possible that the reduced selective pressure of NOD/SCID mice
masks the inherent biological differences of patient tumors.
Table 5. Recurrence-free and overall survival by tumor engraftment and xenograft growht rate.
Recurrence-Free Survival
No. patients Median (Months) 2-year 5-year HR* (95% CI) P
Tumor engraftment
No engraftment 67 16.0 30.3% 15.2% 1.00 (reference)
Engraftment 45 7.0 16.9% 8.5% 2.05 (1.20–3.50) 0.009
Xenograft growth rate
Slow growth 22 10.0 23.5% 0.0% 1.00 (reference)
Rapid growth 23 6.0 10.5% 10.5% 2.37 (0.90–6.25) 0.082
Overall Survival
No. patients Median (Months) 2-year 5-year HR* (95% CI) P
Tumor engraftment
No engraftment 76 21.0 48.7% 16.5% 1.00 (reference)
Engraftment 57 13.0 24.3% 11.2% 1.44 (0.90–2.31) 0.125
Xenograft growth rate
Slow growth 29 14.0 30.0% 9.4% 1.00 (reference)
Rapid growth 28 8.0 18.5% 14.8% 1.63 (0.79–3.38) 0.190
Abbreviations: HR, hazard ratio.
*Cox proportional hazards regression adjusting for patient age, sex, neoadjuvant therapy, adjuvant therapy, American Joint Committee on Cancer stage,
tumor location, tumor grade of differentiation, lymphovascular invasion, and resection margins.
https://doi.org/10.1371/journal.pone.0182855.t005
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The association of molecular alterations with PDAC PDX formation has been controversial.
The focus of this analysis has been on the loss of SMAD4 expression, which has been implicated
in metastatic spread of PDAC [33]. Previously, Garrido-Laguna et al. found that engrafted
tumors were more frequently associated with SMAD4 inactivation [17]. In contrast, in a study
by Jun et al. there was no association between loss of SMAD4 and success of tumor engraftment
[16]. Similarly, our analysis of SMAD4 expression in patient tumors did not find any correlation
with the success or timing of tumor engraftment. Moreover, our study and others have demon-
strated that successfully and unsuccessfully engrafted tumors exhibit a similar distribution of
KRASmutations and comparable expression or mutation of TP53. Collectively, these results
suggest that that single genetic alterations may not be determinant of tumor engraftment, allow-
ing PDX models of PDAC to recapitulate the broad genetic diversity of patient tumors.
As seen in PDX models of other cancers, successful engraftment of PDAC tumors correlates
with shorter recurrence-free and overall survival. In the present study, tumors successfully
engrafted in mice showed significantly poorer overall survival and xenograft formation was an
independent predictor of poor survival. Similarly, Garrido-Laguna et al. showed that patients
whose pancreatic tumors failed to engraft had an 81% reduced risk of death, and Thomas et al.
demonstrated that patients whose tumors successfully engrafted experienced recurrence sig-
nificantly earlier than those whose did not grow [17,18]. Despite the shorter survival of
patients with PDAC that form PDX tumors, most tumors are established in mice 4–5 months
before recurrence in patients undergoing surgical resection. In our cohort of patients with
recurrent disease, xenograft tumors developed a median of 166 days before diagnosis of recur-
rence. Similarly, Thomas et al. detected first palpable signs of tumor formation a median of
134.5 days before radiographic recurrence identification [18]. Given the limited number of
therapeutic options and the variable rate of successful growth, the systematic use of PDX
tumors for real-time chemo-sensitivity testing is not practical at this time. However, by pre-
dicting recurrence months before current surveillance modalities, these models might provide
a window of opportunity for increased surveillance and differentiation of treatment, especially
in patients at higher risk of recurrent disease.
Our study had limitations. The patient population derives from a single referral center,
which may result in variations relative to the general population. For instance, nearly a third of
patients underwent neoadjuvant treatment. However, this was not associated with the rate of
tumor engraftment; moreover, multivariable-adjusted survival models adjusted for different
peri-operative treatment status, minimizing any potential biases. A small proportion (16%) of
patients in our study had metastatic disease at the time of surgery, introducing heterogeneity
in analyses of OS. To address this issue, we conducted a separate analysis of RFS among the
more homogeneous subset of patients with resectable primary tumors and no evidence of met-
astatic disease.
In conclusion, successful establishment of PDAC PDX predicts an increased risk of disease
recurrence and mortality in the original patients. Lymphovascular invasion and lymph node
positivity might reflect an underlying biological mechanism that allows these tumors to estab-
lish and thrive in a new host environment. These models are able to faithfully reproduce the
cancer and stromal architecture from the original tumor, and may therefore be valuable tools
to test new therapeutic alternatives and identify patients who are at very high risk of disease
recurrence following resection.
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